<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006254</url>
  </required_header>
  <id_info>
    <org_study_id>VION-CLI-008</org_study_id>
    <secondary_id>CDR0000068187</secondary_id>
    <secondary_id>CCF-IRB-3663</secondary_id>
    <secondary_id>NCI-V00-1622</secondary_id>
    <nct_id>NCT00006254</nct_id>
  </id_info>
  <brief_title>VNP20009 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune&#xD;
      system and stop cancer cells from growing.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose or minimum effective dose and associated toxic&#xD;
           effects of VNP20009 in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine whether VNP20009 can be detected in tumors after treatment in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine the antitumor effects of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive VNP20009 IV over 4 hours on day 1. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients with stable disease or partial or&#xD;
      complete response (CR) may receive additional courses every 35 days for up to 12 total doses&#xD;
      or 2 courses past a CR.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of VNP20009 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity. An additional 6-9 patients are treated at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-45 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>salmonella VNP20009</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced and/or metastatic solid tumors refractory to&#xD;
             standard curative or palliative therapy and for which no other conventional therapy&#xD;
             exists&#xD;
&#xD;
          -  Measurable or evaluable metastatic disease&#xD;
&#xD;
          -  No brain metastases unless previously treated and no evidence of recurrence&#xD;
&#xD;
          -  No lymphoma or other hematologic malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hematocrit at least 30% (transfusion allowed)&#xD;
&#xD;
          -  No known bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN (3 times ULN if liver metastases&#xD;
             present)&#xD;
&#xD;
          -  PT and PTT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No chronic active hepatitis B&#xD;
&#xD;
          -  No end-stage liver disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No urinary tract stones&#xD;
&#xD;
          -  No end-stage renal disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No known valvular disease&#xD;
&#xD;
          -  No known clinically significant atherosclerotic disease, peripheral vascular disease,&#xD;
             or arterial aneurysm&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No artificial heart valves&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe oxygen-dependent chronic obstructive pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No artificial implant that cannot be removed (e.g., prosthetic hips or knees or other&#xD;
             devices)&#xD;
&#xD;
          -  No permanent central venous catheters&#xD;
&#xD;
          -  No gallstones&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No documented Salmonella infection&#xD;
&#xD;
          -  No tumor fever or fever of unknown origin or cause&#xD;
&#xD;
          -  Daily maximum temperature no greater than 38.0 degrees Celsius&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No documented immunodeficiency&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No history of allergic reaction or hypersensitivity to quinolone or cephalosporin&#xD;
             antibiotics&#xD;
&#xD;
          -  No commercial food handlers, day-care workers, or health-care workers&#xD;
&#xD;
          -  No patients unable to avoid close personal contact with severely immunosuppressed&#xD;
             individuals (e.g., other patients on myelosuppressive cancer chemotherapy)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or&#xD;
             nitrosoureas) and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy and recovered&#xD;
&#xD;
          -  No concurrent steroids that could depress the immune system unless indicated for&#xD;
             severe reactions&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior surgery and recovered&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No concurrent palliative surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from any other prior anticancer therapies&#xD;
&#xD;
          -  No concurrent antibiotics&#xD;
&#xD;
          -  No concurrent immunosuppressives or any other medications that could suppress the&#xD;
             immune system&#xD;
&#xD;
          -  No other concurrent treatment for malignancy&#xD;
&#xD;
          -  No requirement for immediate palliative treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>September 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

